Travel to the Azores


All passengers traveling to or within the Azores, and are holders of a valid EU Digital COVID19 Vaccination Certificate, ie, 14 days after the date of complete vaccination, as issued by the health authorities in each European country, not need to perform screening tests for SARS-CoV-2 infection.

All Portuguese citizens can request the issuance of the Digital Certificate of VACCINATION OR RECOVERY, through the SNS24 portal, European foreign citizens should obtain more information from their national health authority.

In the case of the Digital Certificate of RECOVERY, these are valid for 180 days after recovery.


All passengers can travel to or within the Azores, being holders of the Digital TEST Certificate, already issued by the health authorities of each European country.

For the issuance of the Digital TEST Certificate within 72 hours of your trip, you can carry out the screening test in a network of accredited laboratories of the Regional Government of the Azores, throughout the national territory. All tests carried out during trips to the Azores in one of the agreed laboratories are paid for by the Regional Government of the Azores. After scheduling your test, you must report to the laboratory at the indicated time and day, following the information given.

Laboratories with convention

If your result is negative , you must request the issuance of the Green Digital Test Certificate through the SNS24 portal, , or, in the case of foreign citizens, through your national health authority. Before your trip, you must also register your trip, together with the certificate, on the MySafeAzores platform ( ) for the anticipated validation of the submitted documentation.

Children aged 12 and under can travel without a certificate or test.


Passengers who intend to travel to the Azores from abroad, without COVID19 Digital Certificate, by air or sea, and who come from areas considered by the World Health Organization as active community transmission zones or with active virus transmission chains SARS-CoV-2, are required to carry out a test upon arrival at the island of final destination, unless:

  1. present proof of a certificate issued by an accredited laboratory, nationally or internationally, attesting to the performance of a screening test to SARS-CoV-2, carried out by the RT-PCR methodology, within 72 hours before the departure of the flight or departure of the vessel.
  2. provide proof, in digital or paper, of a certificate attesting that the holder has undergone a rapid antigen test listed in the list drawn up by the European Commission based on the Council Recommendation of January 21, 2021, concerning a common framework for the use and validation of the rapid antigen detection tests for COVID-19 and the mutual recognition of test results in the EU, within the last 48 hours, with a negative result.

If your result is positive, do not go to the airport and contact the health authorities in your area of residence.

If your result is negative, you must register your trip on the My Safe Azores platform ( to allow faster control on arrival in the Azores.

Exceptions to the presentation of the test at the time of travel are:

  1. Vaccination certificate issued by third countries, under reciprocal conditions, containing the following information:
    1. Name(s) and surname(s) of the holder;
    2. Date of birth;
    3. Target disease or agent: COVID -19 (SARS -CoV -2 or one of its variants);
    4. COVID -19 vaccine or prophylaxis;
    5. Name of the vaccine against COVID -19;
    6. Marketing authorization holder or manufacturer of the vaccine against COVID -19;
    7. Number in a series of doses, as well as the total number of doses in the series;
    8. Date of vaccination, indicating the date of the last dose administered;
    9. Member State or third country where the vaccine was administered;
    10. Entity issuing the certificate.
  2. The validity of vaccination certificates issued pursuant to the preceding paragraph is only recognized if their holders have been inoculated with vaccine against COVID – 19 with marketing authorization, pursuant to Regulation (EC) No 726/2004, of the European Parliament and of the Council, of March 31, 2004, establishing community procedures for the authorization and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, namely:
    1. Janssen: COVID -19 Vaccine Janssen;
    2. AstraZeneca: Vaxzevria (formerly COVID -19 Vaccine AstraZeneca);
    3. Modern: Spikevax (formerly COVID -19 Vaccine Moderna);
    4. Pfizer -BioNTech: Comirnaty.
  3. Passengers who present the valid EU COVID Digital Recovery Certificate, as of July 1, 2021, or declaration of high surveillance clinic and isolation measures issued by the public health service relating to SARS-CoV-2, whose validity period is one hundred and eighty days;
  4. Passengers aged twelve or under;
  5. Health professionals in service for the transfer or evacuation of patients and who have up-to-date periodic professional screening, in accordance with the technical standard of the Regional Health Authority in force at the time;
  6. Passengers with disease duly proven by a medical statement attesting to anatomical and/or clinical incompatibility for the performance of the SARS-CoV-2 diagnostic test, through the collection of biological material through the nasopharynx, in which case passengers must previously submit to their visit, at least five working days in advance, to the aforementioned declaration to the Regional Health Authority for validation, without prejudice to carrying out a serological test on arrival in the Autonomous Region of the Azores;
  7. Airline crews that do not travel from the "air" side to the "land" side, in the terminological sense in use at national airports, as well as those traveling on service outside the Autonomous Region of the Azores and returning without having left of the aircraft.
  8. Boarded departing from an island considered to have the lowest risk of transmission and which, in transit to the island of final destination, land at the airports of islands classified as high and medium risk of transmission, provided that they do not travel on the "air" side to the “land” side, in the terminological sense in use at national airports;

Important informations:

  1. If you carry out the test in advance, the test report carried out before the departure of the flight must contain the following information:
    1. Identification of the passenger;
    2. Name of the accredited laboratory where the test was carried out, with mention of the respective certification;
    3. Reference to the use of the RT-PCR methodology;
    4. Reference to the sample of “ nasopharyngeal or oropharyngeal swab ”, “ nasopharyngeal or oropharyngeal exudate ”, “ respiratory sample ” or “ respiratory exudate ”, in the technical meanings recognized by the Regional Health Authority in accordance with the World Health Organization;
    5. Date of testing;
    6. Test result as "negative".
  2. You must present the exam result at check-in in digital or physical format, excluding SMS format.